

PFIZER INC.

This document is provided pursuant to Regulation (EC) No 1901/2006 and Communication (2009/C 28/01)

PROPRIETARY DRUG NAME®/GENERIC DRUG NAME:

filanesib

PROTOCOL NO.:

ARRAY-520-311

EudraCT NUMBER:

2014-001052-39

PROTOCOL TITLE:

The FACTOR Study (Filanesib and Carfilzomib Treatment of Relapsed/Refractory Multiple Myeloma): A Multinational, Randomized, Open-label Phase 3 Study of Filanesib (ARRY-520) + Carfilzomib Versus Single-agent Carfilzomib in Patients With Advanced Multiple Myeloma

Study Centers

Data not available

Study Initiation and Final Completion Dates

Data not available. This study was cancelled prior to enrollment of any study subjects and therefore no data were collected.

Phase of Development:

Phase 3

Study Objectives:

To investigate the efficacy and safety of filanesib + carfilzomib versus single-agent carfilzomib in patients with multiple myeloma who have received at least 2 prior line of therapy.

METHODS

Data not available

RESULTS

Subject Disposition and Demography:

Data not available

Efficacy Results:

Data not available

Safety Results:

Data not available

CONCLUSION:

Data not available. This study was cancelled prior to enrollment of any study subjects and therefore no data were collected.